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Conventional psychiatric diagnosis is founded on symptom
description; this then governs the choice of psychotropic
medication. This purely descriptive approach resembles a
description of diphtheria from the premicrobiology era.
Based on current advances in basic and clinical neuro-
science, we propose inserting an intermediate level of
analysis between psychiatric symptoms and pharmacologic
modes of action. Paradigm 1 is to analyze psychiatric symp-
toms in terms of which higher brain function(s) is (are)
abnormal, ie, symptoms should be analyzed as higher brain
dysfunction: a case study in obsessive-compulsive disorder
reveals pointers in four common symptoms to the higher
functions of working memory, emotional overlay, absence
of voluntary control, and the ability to evaluate personal
mental phenomena. Paradigm 2 is to view psychotropic
drugs as modifying normal higher brain functions, rather
than merely treating symptoms, which they do only sec-
ondarily: thus depression may respond to agents that act on
related aspects of mental life derived from higher brain
functions, eg, the ability  to enhance bonding. We advocate
a strategy in which psychiatric illness is progressively reclas-
sified through knowledge in clinical neuroscience and treat-
ment targets are revised accordingly.
he last decades have been a time of active
research and discovery in the fields of psychotropic med-
ication, the identification and classification of psychi-
atric disorders,and the physiology of higher brain func-
tions, such as emotions, memory, or consciousness.
A very impressive effort has been made at the interna-
tional level to reach a consensus for making reliable psy-
chiatric diagnoses,which represents a huge progress.In
this article, we explore the nature of the relationship
between psychopharmacology, psychiatric symptoma-
tology,and higher brain functions.
Psychotropic medication
Psychotropic drugs,such as chlorpromazine,imipramine,
or diazepam,were developed by astute researchers,at a
time when several neurotransmitters had not yet been
discovered and when little was known about the physi-
ology of neurotransmitters.The modes of action of these
first psychotropic drugs were discovered years after they
had been successfully used clinically,and are still under-
going further study. A psychotropic drug can be
described according to the way in which it influences
receptors,transporters,and enzymes,ie,the cellular sites
of its pharmacological actions.These drugs can be selec-
tive to a greater or lesser extent.There are the so-called
“dirty”drugs that influence a large number of brain sys-
tems. Chlorpromazine is an example of such a non-
selective psychotropic drug as it acts as an antagonist of
many dopaminergic, adrenergic, serotonergic, choliner-
gic, and histaminergic receptors and has a membrane-
stabilizing action. Clozapine is another example of a
drug that acts on many cell-membrane receptors or
transporters; it is difficult to explain why blocking all
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Clinical researchthese systems with clozapine has led to the best results
yet seen in the treatment of schizophrenia. Prescribing
only clozapine to a patient cannot be said to be
monotherapy,because more than 10 different modes of
action may be involved in its clinical effects. On the
other hand, there are psychotropic drugs with a more
selective mode of action, for example, the serotonin 
(5-HT) transporter (5-HTT) blockers (selective sero-
tonin reuptake inhibitors [SSRIs]). When these drugs
are administered, however, physiological systems sub-
serving many brain functions are influenced,as is appar-
ent from the list of their beneficial and adverse effects.
Selectivity is also relative if one considers the number of
intracellular changes that are induced following drug
administration, and the number of different neuronal
circuits that are influenced. For example, an agonist of
the M1 muscarinic receptor,a drug that may be useful in
dementia of the Alzheimer type,has a selective mode of
action.However,this selectivity is only at the cell mem-
brane receptor level; stimulation of this cell membrane
receptor leads,through secondary and tertiary intracel-
lular messengers,
1 to the expression of more than 100
proteins 60 minutes after administration (Nitsch RM,
unpublished data).In the future,clinicians will be able to
explain to their patients that psychotropic drugs modify
protein synthesis in the brain (demanding patients may
ask for the exact list of the proteins that are modified by
their medication!). Moreover, because most drugs dif-
fuse throughout the brain and are not target-selective,
they probably exert their effects mainly via an influence
on volume transmission of several neurotransmitters
rather than via the more classic wired transmission.
As already mentioned, the present approach in psy-
chopharmacology is essentially syndromal. For example,
antidepressants are drugs aimed at treating depressive
symptoms,while antipsychotics are aimed at treating schiz-
ophrenic symptoms.Similarly,antihypertensive drugs are
prescribed in internal medicine to treat high blood pres-
sure. However, a major difference is that internists know
better than psychiatrists what drugs do at the pharmaco-
logical level. Internists know that they either substitute
for a missing compound (eg,insulin),attack an infectious
agent (ie, antibiotics), or “cheat the body” (eg, induce a
dysfunction in normal physiology in order to influence a
symptom). For example, drugs used for cardiac insuffi-
ciency decrease blood volume, increase the muscular
capacity of the myocardium, modify vascular resistance,
lower heart rate, etc. Internists have a clear idea of what
occurs when a patient develops cardiac insufficiency.They
know that a diuretic is a regulator of electrolyte home-
ostasis and so do not call it an “antidyspnea” drug just
because it controls the respiratory difficulties of patients
with cardiac insufficiency. In psychopharmacology, direct
links are often made from receptor or transporter to symp-
toms, without an intermediate analysis of which physio-
logical functions are modified by the medication. Recent
discoveries in the field of antidepressant agents show that
extrapolation from the action of SSRIs action on the 5-
HTT to improvement in mood is a gross simplification.
Indeed,several antidepressants also decrease the expres-
sion of corticotropin-releasing hormone (CRH) in the
hypothalamus and increase the expression of glucocorti-
coid receptors in the hippocampus
2; in addition, they
increase the expression of gonadorelin (LHRH),
3 and of
brain-derived neurotrophic factor (BDNF).
4 These phar-
macological effects might explain, in part, the clinical
effects,through an influence on several brain functions.
Psychiatric disorders
Diagnoses using the Diagnostic and Statistical Manual of
Mental Disorders,Fourth Edition (DSM-IV) and the Inter-
national Statistical Classification of Diseases,10th Revision
(ICD-10) manuals are based on qualitative classification:
a particular disorder is present if the required number of
symptoms is found. Only a few mechanisms have been
established for these disorders.The problems of a descrip-
tive classification have long been recognized,as illustrated
by the following citation,translated from a French book by
Nathan
5:“Until a classification can be based on etiology
and pathogenesis, it does exist but is theoretically and
practically sterile. If we only described symptoms, we
would be like a doctor who described the false-membrane
pharyngitis of diphtheria,while ignoring the microorgan-
ism that provokes the disease.”There are more than 400
clinical codes in the DSM-IV. ICD-10 proposes an even
larger number of clinical entities,because,for each corre-
sponding DSM-IV diagnosis, synonyms and related enti-
ties are mentioned in ICD-10. The validity of some of
these disorders can be questioned: are they independent
entities, do they have different mechanisms, do they
respond to specific treatments? Thinking in terms of direct
links between the actions of psychotropic medications at a
receptor and the changes in symptoms has been fruitful in
the sense that many discoveries were made following this
rather simple paradigm. An amusing example may be
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found in a recent article,
6 where a direct link was made
between receptors and symptoms, ie, between 5-HTT on
blood platelets and romantic love. The study, which was
the work of an Italian group, was based on the fact that
there is a superficial resemblance between obsessive com-
pulsive ideas and romantic fascination. The results were
that subjects in love have a lower number of 5-HTT, as
do patients suffering from obsessive-compulsive disorder.
Applying this linear thinking to the mechanisms of disor-
ders can,however,be risky and it would be like internists
thinking that a cardiac disorder such as hypertension is a
disorder of calcium or β -receptors, just because calcium
blockers or β -blockers are clinically useful in this condi-
tion. The biochemical organization of the brain is better
understood now, and this has consequences for psy-
chopharmacology.The importance of volume versus clas-
sic transmission has been recognized.
7With volume trans-
mission,5-HT,noradrenaline (NA),and other compounds
are secreted into the interstitial space by the axon and
neuron,rather than released into the synaptic cleft.Over-
all, half of serotonergic transmission is said to be volume
transmission,but this proportion varies depending on the
brain structures. Thus, monoamines are classic neuro-
transmitters as well as neuromodulators or neurohor-
mones.Psychotropic drugs act at all these various levels of
monoamine physiology.
Brain physiology and higher 
brain functions
Higher brain functions include perceptions, emotions,
memory, thinking (beliefs), attention, consciousness,
motivation (desire), and many others. These functions
create and regulate our mental world,and the organiza-
tion of the brain in regard to these functions has been
discussed for centuries.René Descartes (1596-1650) rec-
ognized the central role of emotions (or “passions” as
they were then called) by indicating what information or
thought was important for us and what was not. John
Hughlings Jackson (1835-1911) proposed that, when a
hierarchically higher center became dysfunctional, a
more primitive form of the brain function previously
regulated by that center was expressed. Paul MacLean
(1913- ),who worked with James Papez (1883-1958),has
stressed the concept of a triune brain: a reptilian brain
(essentially the brain stem), a paleomammalian brain
(the limbic system), and a neomammalian brain (the
neocortex). The reptilian brain is for basic instincts
(feeding,fighting),the paleomammalian brain deals with
emotions, and the neomammalian brain is responsible
for complex associative functions.The dialogue between
these three brains may be difficult, because only the
neomammalian brain seems capable of handling infor-
mation with verbal and symbolic modalities.
Point-to-point (wired or linear) transmission of informa-
tion is a necessary component of perception and motor
activity according to the concept of modularity: a spe-
cific brain region is mostly responsible for a specific func-
tion.This wired transmission of information is also rele-
vant for higher brain functions, a fact that was elegantly
demonstrated by Downer in a paper published in Nature
in 1961.
8 His paper is about visual gnostic functions and
emotional behavior in split brain monkeys,with the cor-
pus callosum and optic chiasma both cut. In such a
model, information getting to one eye only goes to the
ipsilateral cortex and the two cortices can no longer
exchange information as they usually do through the cor-
pus callosum.The next step was to destroy the amygdala
in one temporal lobe,leaving the other one intact.When
this was done, covering the eye that projected to the
lesioned cortex had no consequences: the monkey
behaved in a normal manner (reacting aggressively to
any human it saw).When the eye projecting to the non-
lesioned cortex was covered, behavior became abnor-
mal, with the monkey being indifferent to the potential
threat of an approaching human; it “saw” the world
through its lesioned amygdala only. This example of a
unilateral Klüver-Bucy syndrome supports the notion of
point-to-point or wired transfer of information,ie,mod-
ularity in behavioral control. It was selective for the
visual modality, since, if the monkey was touched by a
human,it reacted violently,as usual.Research in human
beings who have a lesioned corpus callosum has also
illustrated this modularity of brain functions: in these
studies,it was established that the right cortex had infor-
mation that the left one did not have access to. Brain-
imaging techniques have now opened fields of knowl-
edge far beyond these early and clever analyses. For
example, it has become possible to identify which brain
areas are metabolically active after the intravenous injec-
tion of nicotine in human subjects. Thus, limbic areas
related to higher brain functions such as reward and
emotions are more active,specifically the nucleus accum-
bens,the amygdala,the cingulate,and frontal lobes.
9
The study of higher brain functions is complex,because
each can be analyzed at different levels (from psychol-
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ogy to molecular biology),and because few higher brain
functions are unitary, a fact that can be illustrated with
the many aspects of consciousness. Consciousness can
be described in neurological terms, meaning vigilance
states (awake,asleep,comatose),or in more psycholog-
ical terms,meaning awareness.Awareness refers to many
higher brain functions. There are so many different
things that we can be conscious of (aware of),and we do
not always have words for these categories of con-
sciousness.We do have words for dysfunctions of specific
aspects of consciousness, such as blindness, prosopag-
nosia,and phantom limbs,which are problems of aware-
ness in relation to perception of physical realities.
Alexithymia involves both perception and consciousness,in
the sense that it is concerned with recognizing our emo-
tions and those of others.The capacity to construct a repre-
sentation of a person’s mental world is called the “theory of
mind,” and dysfunctions of this higher brain function are
observed,for instance,in autism.An important question is
how to define higher brain functions:should they be defined
in behavioral terms,in physiological terms,or at the level of
neuronal circuits? To illustrate this question with schizo-
phrenia, should the disorder of thought be approached by
measuring changes in neurophysiological parameters, or
should it be described in terms of the filtering capability of
corticothalamocortical loops,or in terms of neuroanatomi-
cal or biochemical changes? Other issues are the definition
and the taxonomy of higher brain functions. The case of
the emotions is illustrative of these issues.How many basic
emotions are there? How can one classify the many com-
posite (or secondary) emotions? In our text below,we men-
tion the behavioral and psychological level of higher brain
functions, and we discuss some quite basic functions (eg,
memory),as well as composite (derived or secondary) func-
tions (eg,empathy,social dominance,bonding).
Proposals concerning diagnosis
We propose that symptoms should not be merely
described and classified clinically, but also analyzed in
terms of potentially modified higher brain functions.This
proposal can be illustrated by the following case of a 50-
year-old man suffering from an obsessive-compulsive dis-
order with predominant ruminations. If he hears a song
on the radio in the morning,he can have this music in his
mind for the whole day, and, if the text of the song has
emotional connotations, he feels compelled to increase
what he calls his “corrections,”that is,to keep large num-
bers in his head from becoming even larger, by carrying
out mental subtraction.He takes forever to close the door
of his apartment, but can go out without checking when
his friend closes the door.How could these symptoms be
analyzed in terms of higher brain functions? First,it seems
that auditory messages, when they are presented in a
song, are kept in the phonological loops of his working
memory. The second observation is that emotionally
charged information induces or aggravates the symptoms,
a well-known phenomenon in several neurological dis-
orders.The third observation it that he has no voluntary
control over the need for mental calculation,just as we do
not have control over a tremor or a dyskinesia.The fourth
observation is that he has an awareness of these mental
phenomena, and can see them as unusual or abnormal.
Finally,it is difficult for him to conclude that a given situ-
ation is solved and that he can safely move on to the next
action. In order to consider that a given action is safely
finished, one must escape or extinguish the need to con-
tinue checking what has just occurred and what might
occur next. People with obsessive-compulsive disorders
cannot stop checking, but they seem to check mostly
things or activities that are a problem to them;they worry
about “ego-centered,”not general,safety.In summary,for
each of the above aspects, one could investigate which
higher brain functions are abnormal.
Another illustration of how to analyze symptoms in terms
of higher brain functions is given below, for the case of
depression. If a man becomes depressed because he has
not achieved the life goals (education,fame,fortune,etc)
that he has set himself, one might consider that his pre-
frontal cortex is predominantly involved in the causation
of his depression: it would therefore be a case of mainly
neomammalian brain dysfunction. If another man is
depressed because he has suffered two myocardial infarc-
tions within a year,one might consider that the amygdala
and other limbic structures are predominantly involved in
the causation of his depression,in which case it would be
mainly paleomammalian brain dysfunction.Finally,a rep-
tile that seems unhappy in captivity could be suffering
from reptilian brain dysfunction,accompanied by excess
secretion of cortisol.
Our proposal that a given symptom results from the dys-
function of a particular higher brain function remains
schematic.Questions arise such as where does one symp-
tom end and others begin,how often can one isolate one
higher brain function from another, what are the hierar-
chies between global and more selective higher brain
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functions? Despite these questions,we feel that adding an
intermediate level of analysis between psychiatric symp-
toms and pharmacological modes of action would be
fruitful. Indeed, more and more studies are being con-
ducted along these lines.For example,in the field of schiz-
ophrenia,the cognitive abilities of subjects are measured
in the prodromal phase, in the acute decompensation
phase,and under treatment with antipsychotics.An obvi-
ous advantage of linking psychiatric symptoms to higher
brain functions is that the clinician is bound to establish a
list of functions and to consider which of these functions
are normal or abnormal. Indeed, therapies based on the
maintenance and care of body or brain functions that
have remained responsive are usually more successful.
Proposals concerning 
medications
It might be beneficial to consider what normal func-
tion(s) is (are) modified by psychotropic drugs and how
this might be useful in cases of psychiatric disorders.
We illustrate this proposal by listing particular aspects
of our mental life that are derived from higher brain
functions, and that, if influenced by therapeutic agents,
might lead to an improvement in depression.A first func-
tion is related to the tendency to be a dominant subject
within a group: antidepressant agents facilitate domi-
nance in the hierarchical position of animals within their
social group. A second function might be the bonding
process and the need for affection between individuals.
Oxytocin is involved in bonding, but antidepressants
have not yet been developed along that line.γ -Hydroxy-
butyrate (GHB) seems to lead to enhancement of the
pleasure of being with others; analogues of GHB might
therefore act as antidepressants. Sildenafil might be an
antidepressant agent for some men, directly through
reestablishing a sense of bonding and indirectly through
higher levels of testosterone. A third function is stress
and sensitivity to stress; many antidepressant agents
dampen the biological consequences of stress and modify
the level of function of major stress axes.Antagonists to
CRF are also being studied as potential antidepressants.
A fourth function is the construction of beliefs,and their
malleability or lack thereof.A substance that could facil-
itate putting strong ideas or beliefs slightly “out of focus”
would be useful in cases of depressed thoughts or melan-
cholic delusions.
Conclusion
Clinicians describe psychiatric symptoms, but rarely
analyze them in terms of higher brain functions,
although these symptoms certainly result from alter-
ations in these functions. However, establishing direct
links between symptoms, higher brain functions, and
modes of action of psychotropic drugs remains diffi-
cult.While discrete neuronal circuits are being discov-
ered for particular higher brain functions, most psy-
chotropic drugs have an overall effect on the brain,
without much neuroanatomical selectivity. In addition,
we do not have a definitive taxonomy of higher brain
functions.In this article,we have proposed two shifts in
paradigms. First, psychiatric symptoms should be ana-
lyzed in terms of which higher brain function(s) is (are)
abnormal,ie,they should be analyzed as dysfunctions of
higher brain functions. Second, psychotropic drugs
should be seen as modifying normal higher brain func-
tions,rather than merely treating symptoms,which they
do only secondarily. Our proposal may facilitate com-
prehension of the links between psychotropic medica-
tions and their clinical effects.The challenge is to con-
front theoretical and pathophysiological models with
the present descriptive clinical approach, and to estab-
lish a new classification of psychiatric disorders based
on the elaborate psychological and physiological con-
cepts derived from the neurosciences. ❑
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Psicofármacos, trastornos psiquiátricos 
y funciones corticales superiores
El diagnóstico psiquiátrico convencional se basa
en la descripción de los síntomas, y a partir de
esto se hace la elección de los psicofármacos. En
su falta de rigor científico y su potencial de daño
iatrogénico colateral, esta aproximación parece
como una descripción de la difteria en la época
premicrobiológica. En base a los avances actua-
les de las neurociencias (aspectos básicos y clíni-
cos), se propone insertar un nivel intermedio de
análisis entre los síntomas psiquiátricos y los
mecanismos de acción farmacológicos. El paradig-
ma 1 se refiere al análisis de los síntomas psiquiá-
tricos en términos de cuál(es) función(es) cere-
bral0+(es) superior(es) es(son) anormal(es); es
decir, los síntomas se deben analizar como una
disfunción cerebral superior: un estudio de caso
en un trastorno obsesivo compulsivo revela índi-
ces de cuatro síntomas comunes para las funcio-
nes superiores de memoria de trabajo, sobrecar-
ga emocional, ausencia de control voluntario y
capacidad para evaluar fenómenos mentales
personales. El paradigma 2 consiste en ver a los
psicofármacos como modificadores de las fun-
ciones cerebrales superiores normales, más que
sustancias que meramente tratan síntomas, esto
lo realizan sólo secundariamente: así la depre-
sión puede responder a agentes que actúan
sobre aspectos relativos a la vida mental deriva-
dos de funciones cerebrales superiores, por
ejemplo, la capacidad del  -hidroxibutirato para
incrementar el grado de afinidad. Se defiende
una estrategia en la que la enfermedad psiquiá-
trica es reclasificada progresivamente por las
neurociencias y los enfoques terapéuticos se
reformulan a consecuencia de esto.
Médicaments psychotropes, troubles 
psychiatriques et fonctions cérébrales
supérieures
En psychiatrie, le diagnostic est classiquement
posé d’après la description des symptômes cli-
niques et détermine ensuite le choix du traite-
ment psychotrope. L’absence de rigueur scienti-
fique de cette attitude et le risque potentiel
d’effets iatrogènes collatéraux rappelle la situa-
tion dans laquelle on se trouvait pour décrire la
diphtérie à l’ère où la microbiologie n’existait pas
encore. Nous proposons de créer un niveau inter-
médiaire d’analyse entre les symptômes psychia-
triques et les modes d’action pharmacologiques
en se fondant sur les avancées actuelles en neu-
roscience fondamentale et clinique. La première
étape est d’analyser les symptômes psychiatriques
en termes de quelle(s) fonction(s) cérébrale(s)
supérieure(s) est/sont affectée(s) : l’exemple de
l’étude du cas d’un patient souffrant  de trouble
obsessionnel-compulsif a montré que ses symp-
tômes affectent quatre domaines de ses fonctions
supérieures : mémoire immédiate ; élément émo-
tionnel surajouté ; absence de contrôle volontai-
re ; enfin, capacité d'évaluer ses propres méca-
nismes mentaux. La deuxième étape est de
prendre en considération le fait que les traite-
ments psychotropes ont un effet sur l’ensemble
des fonctions cérébrales supérieures normales et
non pas seulement sur les symptômes, leur action
thérapeutique intervenant en fait en un second
temps : ainsi, la dépression pourrait répondre à
des thérapeutiques qui agissent sur les aspects
relationnels de la vie mentale dérivant des fonc-
tions cérébrales supérieures, comme par exemple
au  -hydroxybutyrate qui aurait la faculté d’ac-
croître les liens affectifs. Nous préconisons de
reclasser progressivement les pathologies psy-
chiatriques en se fondant sur les données neuro-
scientifiques et de redéfinir en conséquence les
cibles thérapeutiques.
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